GlassScriptPhysician profile
James M Bohning
NPI 1497927776
$4,779.71
in general payments reported to CMS, 2019-2025
32 companies · $459 in 2025
The $459 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $92.64 · 2021: $82.07 · 2022: $439 · 2023: $1,606 · 2024: $1,520 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,585.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $987.83 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Medtronic, INC. | $551.05 | 2022-2025 | Interstim |
| Janssen Biotech, INC. | $395.43 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $341.19 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $248.79 | 2019-2025 | |
| Celgene Corporation | $232.05 | 2023-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $229.01 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| E.R. Squibb & Sons, L.L.C. | $155.91 | 2023-2024 | Zeposia |
| Genzyme Corporation | $146.31 | 2022-2025 | |
| Celltrion USA INC. | $140.61 | 2024-2025 | Vegzelma |
| Thd America, INC. | $124.23 | 2022 | |
| Madrigal Pharmaceuticals | $113.58 | 2024-2025 | Resmetirom, Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $109.80 | 2024-2025 | Iqirvo, Bylvay |
| Braintree Laboratories, INC. | $108.18 | 2019-2024 | Suflave |
| Ferring Pharmaceuticals INC. | $93.28 | 2019-2023 | Rebyota |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $89.91 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $88.83 | 2023-2024 | Dificid, Zinplava, Zerbaxa |
| Intercept Pharmaceuticals, INC. | $87.23 | 2019-2024 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $80.50 | 2020-2023 | Linzess |
| Aimmune Therapeutics, INC. | $61.42 | 2023-2025 | Zenpep |
| Ardelyx, INC. | $60.47 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.00 | 2023-2024 | Cyltezo |
| Regeneron Healthcare Solutions, INC. | $54.39 | 2023-2024 | Dupixent |
| Daiichi Sankyo INC. | $47.24 | 2022-2023 | Injectafer |
| Boston Scientific Corporation | $47.12 | 2022-2024 | Cre Pro |
| Gilead Sciences, INC. | $27.71 | 2019 | |
| Fresenius Kabi USA, LLC | $21.13 | 2023 | Idacio |
| Sandoz INC. | $18.10 | 2024 | Hyrimoz |
| Pharmacosmos Therapeutics INC. | $16.94 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.30 | 2022 | |
| Qol Medical, LLC | $13.87 | 2023 | Sucraid |
| Allergan, INC. | $13.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bohning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.